Literature DB >> 18233965

Mechanisms of ventricular fibrillation initiation in MADIT II patients with implantable cardioverter defibrillators.

Ryan Anthony1, James P Daubert, Wojciech Zareba, Mark L Andrews, Scott McNitt, Ethan Levine, David T Huang, W Jackson Hall, Arthur J Moss.   

Abstract

BACKGROUND: The availability of stored intracardiac electrograms from implantable defibrillators (ICDs) has facilitated the study of the mechanisms of ventricular tachyarrhythmia onset. This study aimed to determine the patterns of initiation of ventricular fibrillation (VF) in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients along with associated electrocardiogram (ECG) parameters and clinical characteristics.
METHODS: Examination of stored electrograms enabled us to evaluate the rhythm preceding each episode of VF and to calculate (intracardiac) ECG parameters including QT, QT peak (QTp), coupling interval, and prematurity index.
RESULTS: Sixty episodes of VF among 29 patients (mean age 64.4 +/- 2.5 years) were identified. A single ventricular premature complex (VPC) initiated 46 (77%) episodes whereas a short-long-short (SLS) sequence accounted for 14 (23%) episodes. Of the 29 patients studied, 23 patients had VF episodes preceded by a VPC only, two patients with SLS only, and four patients with both VPC and SLS-initiated episodes. There were no significant differences between initiation patterns in regards to the measured ECG parameters; a faster heart rate with SLS initiation (mean RR prior to VF of 655 +/- 104 ms for SLS and 744 +/- 222 ms for VPC) approached significance (P = 0.06). The two patients with SLS only were not on beta-blockers compared to 83% of the VPC patients.
CONCLUSION: Ventricular fibrillation is more commonly initiated by a VPC than by a SLS sequence among the MADIT II population. Current pacing modes designed to prevent bradycardia and pause-dependent arrhythmias are unlikely to decrease the incidence of VPC-initiated episodes of VF.

Entities:  

Mesh:

Year:  2008        PMID: 18233965     DOI: 10.1111/j.1540-8159.2007.00961.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  6 in total

1.  Mode of onset of polymorphic ventricular tachycardia in acute myocardial infarction.

Authors:  Bulent Gorenek; Osman Cengiz; Gulmira Kudaiberdieva; Ilker Durak; Volkan Dogan; Binnur Yasar; Alparslan Birdane; Yuksel Cavusoglu; Necmi Ata
Journal:  Can J Cardiol       Date:  2010 Aug-Sep       Impact factor: 5.223

2.  Analysis of ECG Measures of Cardiac Repolarization in Relation to Arrhythmic Events in an Implantable Cardioverter Defibrillator Population.

Authors:  Bijia Shi; Scott Harding; Peter Larsen
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-06-13       Impact factor: 1.468

3.  [Sandwiched between the single- and triple-chamber ICD: do we still need the dual-chamber ICD?].

Authors:  C W Israel
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2008-12

4.  Improve the prevention of sudden cardiac arrest in emerging countries: the Improve SCA clinical study design.

Authors:  Shu Zhang; Balbir Singh; Diego A Rodriguez; Alexandr Robertovich Chasnoits; Azlan Hussin; Chi-Keong Ching; Dejia Huang; Yen-Bin Liu; Jeffrey Cerkvenik; Sarah Willey; Young-Hoon Kim
Journal:  Europace       Date:  2015-06-01       Impact factor: 5.214

5.  Body mass index, abdominal fatness, and the risk of sudden cardiac death: a systematic review and dose-response meta-analysis of prospective studies.

Authors:  Dagfinn Aune; Sabrina Schlesinger; Teresa Norat; Elio Riboli
Journal:  Eur J Epidemiol       Date:  2018-02-07       Impact factor: 8.082

6.  Cycle length of nonsustanied ventricular tachycardias among ICD patients: implications on subsequent appropriate therapies.

Authors:  Javier Jiménez-Candil; Olga Duran; Armando Oterino; Jendri Pérez; Juan Carlos Castro; Jesús Hernández; José Moríñigo; Manuel Sánchez García; Pedro L Sánchez
Journal:  BMC Cardiovasc Disord       Date:  2021-05-31       Impact factor: 2.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.